TABLE OF CONTENTS
1 INTRODUCTION 57
1.1 OBJECTIVES OF THE STUDY 57
1.2 MARKET DEFINITION 57
1.3 OVERVIEW OF THE ASIA PACIFIC DRUG MODELING SOFTWARE MARKET 57
1.4 CURRENCY AND PRICING 59
1.5 LIMITATIONS 59
1.6 MARKETS COVERED 59
2 MARKET SEGMENTATION 62
2.1 MARKETS COVERED 62
2.2 GEOGRAPHICAL SCOPE 63
2.3 YEARS CONSIDERED FOR THE STUDY 64
2.4 DBMR TRIPOD DATA VALIDATION MODEL 65
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 68
2.6 MULTIVARIATE MODELING 69
2.7 COMPONENT LIFELINE CURVE 69
2.8 DBMR MARKET POSITION GRID 70
2.9 VENDOR SHARE ANALYSIS 71
2.10 MARKET APPLICATION COVERAGE GRID 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73
3 EXECUTIVE SUMMARY 74
3.1 PORTER'S FIVE FORCES MODEL 78
3.2 VALUE CHAIN ANALYSIS 79
3.3 REGULATORY STANDARDS 80
3.4 TECHNOLOGICAL TRENDS 81
3.5 BENEFITS OF DRUG MODELING SOFTWARE 82
4 MARKET OVERVIEW 83
4.1 DRIVERS 85
4.1.1 RISING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES 85
4.1.2 RISING DEMAND FOR NOVEL THERAPIES 87
4.1.3 PRECISION MEDICINE AND INTERVENTION OF AI IN DRUG MODELLING 88
4.2 RESTRAINTS 89
4.2.1 LACK OF QUALITY DATA BASE 89
4.2.2 HIGH COST OF MANUFACTURING OF DRUG MODELLING SOFTWARE 89
4.3 OPPORTUNITIES 90
4.3.1 CLOUD COMPUTING AND BIG DATA ANALYTICS IN DRUG MODELLING 90
4.3.2 INCREASING ADOPTION OF MODELLING TOOLS IN DRUG DISCOVERY 91
4.4 CHALLENGES 91
4.4.1 LACK OF PROCEDURE FOR MULTI-DRUG EFFECT ASSESMENT 91
4.4.2 CHALLENGES WITH MODEL INTERPRETATION 92
5 ASIA PACIFIC DRUG MODELING SOFTWARE MARKET, BY COMPONENTS 93
5.1 OVERVIEW 94
5.1.1 SOFTWARE 97
5.1.1.1 INTEGRATED 98
5.1.1.2 STANDALONE 98
5.1.1.3 LIGAND BASED 98
5.1.1.4 STRUCTURE BASED 98
5.2 SERVICES 98
5.2.1 PROFESSIONAL SERVICES 99
5.2.1.1 CONSULTING AND TRAINING 100
5.2.1.2 INTEGRATION AND IMPLEMENTATION 100
5.2.1.3 SUPPORT AND MAINTENANCE 100
5.2.2 MANAGED SERVICES 100
6 ASIA PACIFIC DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM 101
6.1 OVERVIEW 102
6.2 WINDOWS 105
6.3 LINUX 105
6.4 MAC OS 106
6.5 OTHERS 107
7 ASIA PACIFIC DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE 108
7.1 OVERVIEW 109
7.2 CLOUD BASED 112
7.3 HYBRID-BASED 112
7.4 ON-PREMISES 113
8 ASIA PACIFIC DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE 114
8.1 OVERVIEW 115
8.2 LARGE ENTERPRISE SIZE 118
8.3 SMALL & MEDIUM ENTERPRISE SIZE 118
9 ASIA PACIFIC DRUG MODELING SOFTWARE MARKET, BY APPLICATION 120
9.1 OVERVIEW 121
9.2 GRAPHICAL MOLECULAR MODELING 124
9.3 GENE SEQUENCE ANALYSIS 124
9.4 PROTEIN MODELING 125
9.5 MODELING CRYSTAL STRUCTURES 126
9.6 CHEMINFORMATICS 127
9.7 HIGH THROUGHPUT VIRTUAL SCREENING 128
9.8 GAS & SOLUTION PHASE REACTION 128
9.9 MEDICAL IMAGING 129
9.10 OTHERS 130
10 ASIA PACIFIC DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL 131
10.1 OVERVIEW 132
10.2 SUBSCRIPTION BASED 135
10.2.1 ANNUALLY SUBSCRIPTION 136
10.2.2 MONTHLY SUBSCRIPTION 136
10.3 ONE-TIME LICENSE 136
10.3.1 GROUP LICENSE 137
10.3.2 DESKTOP LICENSE 137
10.3.3 OTHERS 137
11 ASIA PACIFIC DRUG MODELING SOFTWARE MARKET, BY END USER 138
11.1 OVERVIEW 139
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 142
11.2.1 LARGE ENTERPRISE SIZE 143
11.2.2 SMALL & MEDIUM ENTERPRISE SIZE 143
11.3 CONTRACT RESEARCH ORGANIZATIONS 143
11.3.1 LARGE ENTERPRISE SIZE 144
11.3.2 SMALL & MEDIUM ENTERPRISE SIZE 144
11.4 RESEARCH INSTITUTES 144
11.4.1 LARGE ENTERPRISE SIZE 145
11.4.2 SMALL & MEDIUM ENTERPRISE SIZE 145
11.5 REGULATORY AUTHORITIES 145
11.5.1 LARGE ENTERPRISE SIZE 146
11.5.2 SMALL & MEDIUM ENTERPRISE SIZE 147
11.6 OTHERS 147
11.6.1 LARGE ENTERPRISE SIZE 148
11.6.2 SMALL & MEDIUM ENTERPRISE SIZE 148
12 ASIA PACIFIC DRUG MODELING SOFTWARE MARKET, BY REGION 149
12.1 ASIA-PACIFIC 150
12.1.1 CHINA 161
12.1.2 JAPAN 166
12.1.3 SOUTH KOREA 171
12.1.4 INDIA 176
12.1.5 AUSTRALIA 181
12.1.6 SINGAPORE 186
12.1.7 THAILAND 191
12.1.8 INDONESIA 196
12.1.9 PHILIPPINES 201
12.1.10 MALAYSIA 206
12.1.11 NEW ZEALAND 211
12.1.12 VIETNAM 216
12.1.13 TAIWAN 221
12.1.14 REST OF ASIA-PACIFIC 226
13 ASIA PACIFIC DRUG MODELING SOFTWARE MARKET: COMPANY LANDSCAPE 227
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 227
14 SWOT ANALYSIS 228
15 ASIA PACIFIC DRUG MODELING SOFTWARE MARKET, COMPANY PROFILE 229
15.1 DASSAULT SYSTEMES 229
15.1.1 COMPANY SNAPSHOT 229
15.1.2 REVENUE ANALYSIS 229
15.1.3 COMPANY SHARE ANALYSIS 230
15.1.4 PRODUCT PORTFOLIO 230
15.1.5 RECENT DEVELOPMENT 230
15.2 AMAZON WEB SERVICES, INC. OR ITS AFFILIATES.(A SUBSIDIARY OF AMAZON) 231
15.2.1 COMPANY SNAPSHOT 231
15.2.2 REVENUE ANALYSIS 231
15.2.3 COMPANY SHARE ANALYSIS 232
15.2.4 PRODUCT PORTFOLIO 232
15.2.5 RECENT DEVELOPMENTS 232
15.3 CERTARA, USA. 233
15.3.1 COMPANY SNAPSHOT 233
15.3.2 REVENUE ANALYSIS 233
15.3.3 COMPANY SHARE ANALYSIS 234
15.3.4 PRODUCT PORTFOLIO 234
15.3.5 RECENT DEVELOPMENTS 234
15.4 SCHRDINGER, INC. 235
15.4.1 COMPANY SNAPSHOT 235
15.4.2 REVENUE ANALYSIS 235
15.4.3 COMPANY SHARE ANALYSIS 236
15.4.4 PRODUCT PORTFOLIO 236
15.4.5 RECENT DEVELOPMENT 236
15.5 CRESSET. 237
15.5.1 COMPANY SNAPSHOT 237
15.5.2 COMPANY SHARE ANALYSIS 237
15.5.3 PRODUCT PORTFOLIO 238
15.5.4 RECENT DEVELOPMENTS 238
15.6 ACELLERA LTD 239
15.6.1 COMPANY SNAPSHOT 239
15.6.2 PRODUCT PORTFOLIO 239
15.6.3 RECENT DEVELOPMENTS 239
15.7 ARGUSLAB 240
15.7.1 COMPANY SNAPSHOT 240
15.7.2 PRODUCT PORTFOLIO 240
15.7.3 RECENT DEVELOPMENT 240
15.8 ATOMWISE INC. 241
15.8.1 COMPANY SNAPSHOT 241
15.8.2 PRODUCT PORTFOLIO 241
15.8.3 RECENT DEVELOPMENT 241
15.9 BC PLATFORMS 242
15.9.1 COMPANY SNAPSHOT 242
15.9.2 PRODUCT PORTFOLIO 242
15.9.3 RECENT DEVELOPMENTS 243
15.10 BIOSOLVEIT GMBH 244
15.10.1 COMPANY SNAPSHOT 244
15.10.2 PRODUCT PORTFOLIO 244
15.10.3 RECENT DEVELOPMENT 244
15.11 DOTMATICS 245
15.11.1 COMPANY SNAPSHOT 245
15.11.2 PRODUCT PORTFOLIO 245
15.11.3 RECENT DEVELOPMENTS 246
15.12 GENECODE 247
15.12.1 COMPANY SNAPSHOT 247
15.12.2 PRODUCT PORTFOLIO 247
15.12.3 RECENT DEVELOPMENT 247
15.13 INSILICOTRIALS TECHNOLOGIES. 248
15.13.1 COMPANY SNAPSHOT 248
15.13.2 PRODUCT PORTFOLIO 248
15.13.3 RECENT DEVELOPMENTS 249
15.14 NANOME INC. 250
15.14.1 COMPANY SNAPSHOT 250
15.14.2 PRODUCT PORTFOLIO 250
15.14.3 RECENT DEVELOPMENT 250
15.15 OPTIBRIUM, LTD. 251
15.15.1 COMPANY SNAPSHOT 251
15.15.2 PRODUCT PORTFOLIO 251
15.15.3 RECENT DEVELOPMENT 251
15.16 PHARMACELERA 252
15.16.1 COMPANY SNAPSHOT 252
15.16.2 PRODUCT PORTFOLIO 252
15.16.3 RECENT DEVELOPMENT 252
15.17 SIMULATIONS PLUS. 253
15.17.1 COMPANY SNAPSHOT 253
15.17.2 REVENUE ANALYSIS 254
15.17.3 COMPANY SHARE ANALYSIS 255
15.17.4 PRODUCT PORTFOLIO 255
15.17.5 RECENT DEVELOPMENT 256
15.18 THE SCRIPPS RESEARCH INSTITUTE 257
15.18.1 COMPANY SNAPSHOT 257
15.18.2 PRODUCT PORTFOLIO 257
15.18.3 RECENT DEVELOPMENT 257
15.19 VERISIM LIFE. 258
15.19.1 COMPANY SNAPSHOT 258
15.19.2 PRODUCT PORTFOLIO 258
15.19.3 RECENT DEVELOPMENTS 258
15.20 XTALPI INC. 259
15.20.1 COMPANY SNAPSHOT 259
15.20.2 PRODUCT PORTFOLIO 259
15.20.3 RECENT DEVELOPMENT 259
15.21 XYBION DIGITAL INC. 260
15.21.1 COMPANY SNAPSHOT 260
15.21.2 REVENUE ANALYSIS 260
15.21.3 PRODUCT PORTFOLIO 261
15.21.4 RECENT DEVELOPMENT 261
16 QUESTIONNAIRE 262
17 RELATED REPORTS 266

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.